Discovery of Novel Serum Biomarkers for Prenatal Down Syndrome Screening by Integrative Data Mining

Background To facilitate the experimental search for novel maternal serum biomarkers in prenatal Down Syndrome screening, we aimed to create a set of candidate biomarkers using a data mining approach. Methodology/Principal Findings Because current screening markers are derived from either fetal liver or placental trophoblasts, we reasoned that new biomarkers can primarily be found to be derived from these two tissues. By applying a three-stage filtering strategy on publicly available data from different sources, we identified 49 potential blood-detectable protein biomarkers. Our set contains three biomarkers that are currently widely used in either first- or second-trimester screening (AFP, PAPP-A and fβ-hCG), as well as ten other proteins that are or have been examined as prenatal serum markers. This supports the effectiveness of our strategy and indicates the set contains other markers potentially applicable for screening. Conclusions/Significance We anticipate the set will help support further experimental studies for the identification of new Down Syndrome screening markers in maternal blood.

[1]  H. Cuckle,et al.  Placental protein 13 as a first trimester screening marker for aneuploidy , 2009, Prenatal diagnosis.

[2]  H. Cuckle,et al.  ADAM12s as a first‐trimester screening marker of trisomy , 2009, Prenatal diagnosis.

[3]  J. Pennings,et al.  Bead‐based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening , 2009, Prenatal diagnosis.

[4]  J. Loeber,et al.  First‐trimester Down syndrome screening performance in the Dutch population; how to achieve further improvement? , 2009, Prenatal diagnosis.

[5]  K. Nicolaides,et al.  Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks. , 2009, American journal of obstetrics and gynecology.

[6]  S. Antonarakis,et al.  Genotype–phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21 , 2009, European Journal of Human Genetics.

[7]  H. Cuckle,et al.  Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies , 2008, Prenatal diagnosis.

[8]  G. Tsangaris,et al.  Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma , 2008, Prenatal diagnosis.

[9]  M. Schuemie,et al.  Anni 2.0: a multipurpose text-mining tool for the life sciences , 2008, Genome Biology.

[10]  David S. Wishart,et al.  Nucleic Acids Research Polysearch: a Web-based Text Mining System for Extracting Relationships between Human Diseases, Genes, Mutations, Drugs Polysearch: a Web-based Text Mining System for Extracting Relationships between Human Diseases, Genes, Mutations, Drugs and Metabolites , 2008 .

[11]  K. Spencer,et al.  Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21 , 2008, Prenatal diagnosis.

[12]  N. Uldbjerg,et al.  First‐trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled? , 2008, Prenatal diagnosis.

[13]  Wei Xiong,et al.  Identification of candidate cancer genes involved in human retinoblastoma by data mining , 2008, Child's Nervous System.

[14]  S. Sifakis,et al.  Human Placental Growth Hormone Is Increased in Maternal Serum in Pregnancies Affected by Down Syndrome , 2008, Fetal Diagnosis and Therapy.

[15]  T. Heidmann,et al.  Human endogenous retrovirus-FRD envelope protein (syncytin 2) expression in normal and trisomy 21-affected placenta , 2008, Retrovirology.

[16]  Y. Yaron,et al.  Genome-wide expression analysis of cultured trophoblast with trisomy 21 karyotype. , 2007, Human reproduction.

[17]  E. Diamandis,et al.  Proteomics Analysis of Human Amniotic Fluid *S , 2007, Molecular & Cellular Proteomics.

[18]  Mary E D'Alton,et al.  Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. , 2007, Journal of proteome research.

[19]  B. No̸rgaard-Pedersen,et al.  Human placental lactogen is a first‐trimester maternal serum marker of Down syndrome , 2007, Prenatal diagnosis.

[20]  G. Tsangaris,et al.  Proteomic analysis of amniotic fluid in pregnancies with Down syndrome , 2006, Proteomics.

[21]  Lakshmanan K. Iyer,et al.  A combined approach to data mining of textual and structured data to identify cancer-related targets , 2006, BMC Bioinformatics.

[22]  D. Patterson,et al.  History of genetic disease: Down syndrome and genetics — a case of linked histories , 2005, Nature Reviews Genetics.

[23]  S. Fisher,et al.  Trisomy 21 is associated with variable defects in cytotrophoblast differentiation along the invasive pathway , 2004, American journal of medical genetics. Part A.

[24]  J. Richtsmeier,et al.  A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes , 2004, Science.

[25]  F. Corrado,et al.  Placental growth hormone in Down's syndrome screening. , 2004, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[26]  S. South,et al.  Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. , 2004, Genome research.

[27]  S. Antonarakis,et al.  Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. , 2004, Genome research.

[28]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Lubec,et al.  Proteomic determination of metabolic enzymes of the amnion cell: Basis for a possible diagnostic tool? , 2004, Proteomics.

[30]  A. Orth,et al.  Large-scale analysis of the human and mouse transcriptomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. N. Lee,et al.  Raised maternal serum placenta growth factor concentration during the second trimester is associated with Down syndrome , 2002, Prenatal diagnosis.

[32]  G. Dalgliesh,et al.  Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies. , 2001, Placenta.

[33]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[34]  J. Connor,et al.  Placental synthesis of oestriol in Down's syndrome pregnancies. , 2000, Placenta.

[35]  E. Wallace,et al.  Amniotic fluid levels of dimeric inhibins, pro‐αC inhibin, activin A and follistatin in Down's syndrome , 1999, Clinical endocrinology.

[36]  W. Engel,et al.  Maternal Serum Placental Growth Hormone and Insulinlike Growth Factor Binding Proteins 1 and 3 in Pregnancies Affected by Fetal Aneuploidy and Other Abnormalities: Implications for Prenatal Diagnosis of Trisomy 21 , 1998, Fetal Diagnosis and Therapy.

[37]  J. Canick,et al.  Second trimester levels of maternal serum total activin A and placental inhibin/activin alpha and betaA subunit messenger ribonucleic acids in Down syndrome pregnancy. , 1998, European journal of endocrinology.

[38]  N. Wald,et al.  Combining Ultrasound and Biochemistry in First‐Trimester Screening for Down's syndrome , 1997, Prenatal diagnosis.

[39]  Burton L. Shapiro,et al.  Whither Down syndrome critical regions? , 1997, Human Genetics.

[40]  J. Canick,et al.  Second Trimester Levels of Maternal Serum Inhibi A, Total Inhibin, α Inhibin Precursor, and Activin in Down's Syndrome Pregnancy , 1996, Journal of medical screening.

[41]  R. Hume,et al.  Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunological characterization of the hepatic, renal, and adrenal enzymes. , 1994, Endocrinology.

[42]  J. Canick,et al.  Maternal serum screening for Down's syndrome in early pregnancy. , 1988, BMJ.

[43]  N J Wald,et al.  Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alphafetoprotein level , 1988, British journal of obstetrics and gynaecology.

[44]  H. Cuckle,et al.  Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha‐fetoprotein level , 1987, British journal of obstetrics and gynaecology.

[45]  J. McPherson,et al.  A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes , 2022 .